1. Home
  2. IMMX vs NAKA Comparison

IMMX vs NAKA Comparison

Compare IMMX & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMX
  • NAKA
  • Stock Information
  • Founded
  • IMMX 2014
  • NAKA 2019
  • Country
  • IMMX United States
  • NAKA United States
  • Employees
  • IMMX N/A
  • NAKA N/A
  • Industry
  • IMMX Medicinal Chemicals and Botanical Products
  • NAKA
  • Sector
  • IMMX Health Care
  • NAKA
  • Exchange
  • IMMX Nasdaq
  • NAKA Nasdaq
  • Market Cap
  • IMMX 65.5M
  • NAKA 72.8M
  • IPO Year
  • IMMX 2021
  • NAKA 2024
  • Fundamental
  • Price
  • IMMX $2.19
  • NAKA $10.13
  • Analyst Decision
  • IMMX Strong Buy
  • NAKA
  • Analyst Count
  • IMMX 1
  • NAKA 0
  • Target Price
  • IMMX $7.00
  • NAKA N/A
  • AVG Volume (30 Days)
  • IMMX 250.2K
  • NAKA 685.4K
  • Earning Date
  • IMMX 08-08-2025
  • NAKA 08-05-2025
  • Dividend Yield
  • IMMX N/A
  • NAKA N/A
  • EPS Growth
  • IMMX N/A
  • NAKA N/A
  • EPS
  • IMMX N/A
  • NAKA N/A
  • Revenue
  • IMMX N/A
  • NAKA $2,239,936.00
  • Revenue This Year
  • IMMX N/A
  • NAKA N/A
  • Revenue Next Year
  • IMMX N/A
  • NAKA N/A
  • P/E Ratio
  • IMMX N/A
  • NAKA N/A
  • Revenue Growth
  • IMMX N/A
  • NAKA N/A
  • 52 Week Low
  • IMMX $1.26
  • NAKA $0.65
  • 52 Week High
  • IMMX $3.20
  • NAKA $34.77
  • Technical
  • Relative Strength Index (RSI)
  • IMMX 39.38
  • NAKA 47.15
  • Support Level
  • IMMX $2.11
  • NAKA $9.31
  • Resistance Level
  • IMMX $2.39
  • NAKA $10.81
  • Average True Range (ATR)
  • IMMX 0.21
  • NAKA 2.31
  • MACD
  • IMMX -0.03
  • NAKA 0.09
  • Stochastic Oscillator
  • IMMX 9.52
  • NAKA 33.72

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

About NAKA Kindly MD Inc. Common Stock

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Share on Social Networks: